The S&P 500 had a good week due to the impressive start of Q1 earnings and favorable inflation data. In March, the consumer price index rose 5%, lower than the previous month's 6%, and met economists' expectations.
Inovio to Plunge Ahead of Earnings Report
Information is not investment advice
About the company
Inovio Pharmaceuticals Inc (INO) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines to treat and prevent various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology.
When the pandemic roiled America in 2020, COVID stocks, including Inovio, gained momentum. Robinhood named Inovio as one of the top 10 most traded stocks on its platform in April 2020, putting Inovio in line with Microsoft (MSFT), Disney (DIS), and Tesla (TSLA). However, the company hasn't been successful in developing a vaccine.
Initially, Inovio announced plans to develop COVID-19 vaccines targeting the recently discovered Omicron variant, which boosted the stock. However, in March 2022, Inovio stated that it paused the development of its phase 3 INO-4800 trial.
The company announced an update of the strategy on the Q1, 2022 earnings call and its more recent CEO presentation at Jefferies 2022 Global Healthcare Conference in June 2022.
CEO Shea described the situation as follows:
"As the COVID-19 pandemic evolves towards the endemic phase, the need for booster vaccines to protect against severe illness and death represents a growing and strategic opportunity. In light of this, we now believe that Inovio can have the greatest impact and serve the most pressing public health needs by focusing on the COVID vaccine in our heterologous booster strategy".
Inovio Pharmaceuticals Inc will release the Q2 2022 financial results on August 9, after the market close (23:30 GMT+3). Following the release, INOVIO will host a live conference call to discuss the financial statement and provide a general business update.
What to expect?
The recent history shows the stock usually falls ahead of earnings reports on expectations of worse-than-expected results. Moreover, after the two latest reports (May 10, 2022, and March 01, 2022), the price opened lower with a gap and returned to growth the next day.
In Q2 2022, the company didn't succeed in drug development, and actual financial results will likely underperform the expectations. Therefore, FBS analysts believe the stock might plunge ahead of the report.
INO, H4 chart
Resistance: $2.27, $2.35
Support: $1.94, $1.83, $1.73
On Friday, July 29, the stock dropped out of the descending channel despite the growth of the US stock indices, highlighting its weakness ahead of the earnings report.
If the price doesn't return inside the channel on Monday, the bears will be able to bring it down to the $1.73, 61.8 Fibonacci level. Moreover, the breakout of $1.73 opens the way to $1.40.
Do you want to get updates Live? Subscribe to the @FBSAnalytics Telegram Channel where I post more daily trade ideas!
FAANG stocks started recovering. Which ones are the best according to fundamental analysis?
The previous year 2022, was undoubtedly tumultuous for the stock markets, with several stocks plummeting across multiple industries. Analysts have blamed the hard times on inflation, hawkish federal reserve policies, an impending global recession, and the ongoing crisis in Ukraine. This year, however, we're beginning to see some recovery in the stock markets. This article will find a few stocks worth buying this year.
Greetings, fellow forex traders! Exciting news for those with an eye on the Australian market - the upcoming interest rate decision could be good news for Aussies looking to refinance or take out new loans. The Mortgage and Finance Association Australia CEO, Anja Pannek, has...
Hold onto your hats, folks! The Japanese yen took a nosedive after the Bank of Japan (BOJ) left its ultra-loose policy settings unchanged, including its closely watched yield curve control (YCC) policy. But wait, there's more! The BOJ also removed its forward guidance, which had previously pledged to keep interest rates at current or lower levels. So, what's the scoop? Market expectations had been subdued going into the meeting, but some were still hoping for tweaks to the forward guidance to prepare for an eventual exit from the bank's massive stimulus